Government Accountability Office Calls for FDA to Finalize Advisory Committee Conflict of Interest Guidance

The Government Accountability Office (GAO) has highlighted significant shortcomings in the Food and Drug Administration’s (FDA) management of advisory committee member financial conflicts of interest. According to the GAO’s review, the FDA has not adequately communicated its criteria for determining whether committee members should participate in meetings, a situation that has persisted for over a decade.

Despite a law mandating the establishment of clear guidance, the FDA has yet to finalize this crucial framework. The lack of transparency extends to the agency’s website, which does not provide information on how conflicts are assessed for both committee members and guest speakers, leaving stakeholders in the dark about potential biases.

The GAO’s recommendations urge the FDA to set a definitive timeline for issuing this guidance and to enhance transparency by publicly disclosing its decision-making processes regarding conflicts of interest. This call to action underscores the need for improved governance to maintain the integrity of advisory committees and bolster public trust in the FDA’s regulatory processes.